NRx Pharmaceuticals Inc Net Assets
NRx Pharmaceuticals Inc net assets. Based on the latest financial reports, NRx Pharmaceuticals Inc (NRXPW) has net assets worth $-13.82 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.90 Million) and total liabilities ($25.72 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore NRx Pharmaceuticals Inc equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-13.82 Million |
| % of Total Assets | -116.07% |
| Annual Growth Rate | N/A |
| 5-Year Change | -176.6% |
| 10-Year Change | N/A |
| Growth Volatility | 106.65 |
Net Assets of NRx Pharmaceuticals Inc (2017–2025)
Net assets of NRx Pharmaceuticals Inc from 2017 to 2025. This chart illustrates how NRx Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. See NRXPW equity to assets ratio to measure how much of total assets are equity-financed.
Annual Net Assets for NRx Pharmaceuticals Inc (2017–2025)
The table below shows the annual net assets of NRx Pharmaceuticals Inc from 2017 to 2025. For live market cap and overall valuation, see NRXPW market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-15.94 Million | +31.37% |
| 2024-12-31 | $-23.22 Million | -97.93% |
| 2023-12-31 | $-11.73 Million | -258.36% |
| 2022-12-31 | $7.41 Million | -64.39% |
| 2021-12-31 | $20.81 Million | +147.53% |
| 2020-12-31 | $-43.77 Million | -248.37% |
| 2019-12-31 | $29.50 Million | -57.58% |
| 2018-12-31 | $69.54 Million | +0.10% |
| 2017-12-31 | $69.47 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to NRx Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 30678996700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
NRx Pharmaceuticals Inc Net Assets Breakdown (December 2025)
NRx Pharmaceuticals Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $32.00K | % |
| Other Components | $290.93 Million | % |
| Total Equity | $-15.94 Million | 100.00% |
NRx Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of NRx Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Housing Development and Infrastructure Limited
NSE:HDIL
|
$132.52 |
|
VIFRANA
RO:BIOW
|
$166.83 |
|
Mammoth Minerals Limited
AU:M79
|
$167.65 |
|
Seed Capital Solutions Plc
LSE:SCSP
|
$169.19 |
|
CuriosityStream Inc
NASDAQ:CURIW
|
$116.21 |
|
Versus Systems Inc
NASDAQ:VSSYW
|
$115.40 |
|
Pathkey.ai Ltd
AU:PKY
|
$103.92 |
|
Us1 Critical Minerals Limited
AU:USC
|
$93.86 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NRx Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -23,223,000 to -15,937,000, a change of 7,286,000.
- Net loss of 28,622,000 reduced equity.
- New share issuances of 15,860,000 increased equity.
- Other factors increased equity by 20,048,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-28.62 Million | -179.59% |
| Share Issuances | $15.86 Million | +99.52% |
| Other Changes | $20.05 Million | +125.8% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares NRx Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $76.89 | $0.01 | x |
| 2018-12-31 | $77.91 | $0.01 | x |
| 2019-12-31 | $57.98 | $0.01 | x |
| 2020-12-31 | $-80.08 | $0.01 | x |
| 2021-12-31 | $0.44 | $0.01 | x |
| 2022-12-31 | $0.11 | $0.01 | x |
| 2023-12-31 | $-1.55 | $0.01 | x |
| 2024-12-31 | $-2.21 | $0.01 | x |
| 2025-12-31 | $-0.74 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NRx Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2336.49%
- • Asset Turnover: 0.09x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-109.17%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -0.15% | 0.00% | 0.00x | 1.00x | $-7.05 Million |
| 2018 | 0.10% | 6.07% | 0.02x | 1.02x | $-6.89 Million |
| 2019 | 1.38% | 33.87% | 0.04x | 1.09x | $-2.54 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-47.40 Million |
| 2021 | -447.29% | 0.00% | 0.00x | 1.57x | $-95.14 Million |
| 2022 | -536.56% | 0.00% | 0.00x | 3.48x | $-40.49 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-28.98 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-22.80 Million |
| 2025 | 0.00% | -2336.49% | 0.09x | 0.00x | $-27.03 Million |
Industry Comparison
This section compares NRx Pharmaceuticals Inc's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NRx Pharmaceuticals Inc (NRXPW) | $-13.82 Million | -0.15% | N/A | $129.52 |
| Advent Technologies Holdings Inc (ADNWW) | $13.45 Million | -530.91% | 1.58x | $28.31 |
| AIxCrypto Holdings, Inc. (AIXC) | $-148.12K | 0.00% | 0.00x | $21.32 Million |
| AmpliTech Group Inc (AMPGW) | $-220.24K | 0.00% | 0.00x | $716.18 |
| Arko Corp (ARKOW) | $224.17 Million | 4.89% | 3.81x | $25.17 |
| Aris Mining Corporation (ARMN) | $245.68 Million | -1.38% | 0.83x | $3.93 Billion |
| Aberdeen Standard Global Infrastructure Income Fund (ASGI) | $482.92 Million | 1.71% | 0.01x | $472.62 Million |
| Atlas Corp (ATCOL) | $5.20 Billion | 12.93% | 2.30x | $244.80K |
| Auddia Inc (AUUDW) | $-9.09 Million | 0.00% | 0.00x | $372.87 |
| BriaCell Therapeutics Corp (BCTXW) | $9.33 Million | -3.95% | 0.01x | $8.51 |
| Blaize Holdings, Inc. Warrants (BZAIW) | $-70.54 Million | 0.00% | 0.00x | $330.55K |
About NRx Pharmaceuticals Inc
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone… Read more